Cessatech A/S announced that the pivotal trial 0205 has now been initiated with the dosing of the first patient. The trial will investigate the postoperative analgesic efficacy of CT001, in adult participants following impacted mandibular third molar extraction, a randomised, double-blind placebo controlled trial with 220 patients. The paediatric investigation plan (PIP) for CT001 nasal spray has been approved by the European Medicines Agency, and trial 0205 is part of the clinical development plan for treatment of acute pain in children. First patient has been dosed in pivotal trial of lead candidate CT001. The pivotal trial, trial 0205, will investigate the postoperative analgesic efficacy of CT001, in adult participants following impacted mandibular third molar extraction, a randomised, double-blind placebo controlled trial with 220 patients. Patient recruitment has now started, and anticipate to finalise recruitment by the first part of 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.94 DKK | -4.50% | -1.33% | -18.18% |
02-29 | Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
- Stock Market
- Equities
- CESSA Stock
- News Cessatech A/S
- Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate